Drug interactions
Netupitant-palonosetron + Selegiline
Severity: Moderate
Netupitant-palonosetron and Selegiline: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Palonosetron has been linked to serotonin syndrome when given with serotonergic agents including MAO inhibitors. Selegiline, particularly at higher oral doses or as transdermal therapy for depression, increases serotonergic activity. The combination may cause neuromuscular, autonomic and mental status changes.
What this interaction means in plain words
Netupitant-palonosetron and Selegiline can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Netupitant-palonosetron belongs to Gastrointestinal Tract; Selegiline belongs to Central Nervous System.
Why it happens
Additive serotonergic effects from MAO inhibition and 5-HT3 antagonism; the precise mechanism is not established.
What to do
Monitor for serotonin syndrome during and after antiemetic dosing, especially in patients on antidepressant-dose selegiline. Stop the offending drugs and provide supportive care if toxicity occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Netupitant-palonosetron and Selegiline, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Netupitant-palonosetron
- Apomorphine + Netupitant-palonosetron Contraindicated
- Flibanserin + Netupitant-palonosetron Contraindicated
- Apalutamide + Netupitant-palonosetron Major
- Avapritinib + Netupitant-palonosetron Major
- Carbamazepine + Netupitant-palonosetron Major
- Cobimetinib + Netupitant-palonosetron Major
Other interactions of Selegiline
- Amitriptyline + Selegiline Contraindicated
- Amoxapine + Selegiline Contraindicated
- Atomoxetine + Selegiline Contraindicated
- Benzphetamine + Selegiline Contraindicated
- Brimonidine + Selegiline Contraindicated
- Buprenorphine long-acting + Selegiline Contraindicated
Frequently asked questions
Can I take Netupitant-palonosetron with Selegiline?
MediHelp rates the interaction as moderate. Netupitant-palonosetron and Selegiline can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Palonosetron has been linked to serotonin syndrome when given with serotonergic agents including MAO inhibitors. Selegiline, particularly at higher oral doses or as transdermal therapy for depression, increases serotonergic activity. The combination may cause neuromuscular, autonomic and mental status changes.
How serious is the interaction between Netupitant-palonosetron and Selegiline?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for serotonin syndrome during and after antiemetic dosing, especially in patients on antidepressant-dose selegiline. Stop the offending drugs and provide supportive care if toxicity occurs.
What other medicines interact with Netupitant-palonosetron?
MediHelp also lists interactions of Netupitant-palonosetron with, for example, Apomorphine, Flibanserin, Apalutamide. The full list is on the Netupitant-palonosetron page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
